|
NL297170A
(enExample)
|
1963-04-04 |
1900-01-01 |
|
|
|
US3558618A
(en)
|
1968-04-01 |
1971-01-26 |
Dow Chemical Co |
Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones
|
|
GB1383409A
(en)
|
1972-09-09 |
1974-02-12 |
Pfizer Ltd |
Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
|
|
US4122274A
(en)
|
1977-05-25 |
1978-10-24 |
Bristol-Myers Company |
3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
|
|
JPS56150091A
(en)
|
1980-03-28 |
1981-11-20 |
Janssen Pharmaceutica Nv |
3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture
|
|
US4342870A
(en)
|
1980-03-28 |
1982-08-03 |
Janssen Pharmaceutica N.V. |
Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
|
|
JPS5852307A
(ja)
|
1981-09-22 |
1983-03-28 |
Hitachi Chem Co Ltd |
水分散樹脂組成物
|
|
US5089633A
(en)
|
1987-04-28 |
1992-02-18 |
Georgia Tech Research Corporation |
Substituted isocoumarins
|
|
US5599816A
(en)
|
1990-05-02 |
1997-02-04 |
Abbott Laboratories |
Quinolizinone type compounds
|
|
EP0640083A1
(en)
|
1992-05-13 |
1995-03-01 |
E.I. Du Pont De Nemours And Company |
Substituted pyrido 1,2-a]pyrimidinone derivatives as fungicides
|
|
DE69435005T2
(de)
|
1993-05-11 |
2008-04-17 |
The University Of North Carolina At Chapel Hill |
Antisense Oligonukleotide die anomales Splicing verhindern und deren Verwendung
|
|
WO1996039407A1
(en)
|
1995-06-06 |
1996-12-12 |
Abbott Laboratories |
Quinolizinone type compounds
|
|
US5916916A
(en)
|
1996-10-10 |
1999-06-29 |
Eli Lilly And Company |
1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
|
|
US5869500A
(en)
|
1996-12-13 |
1999-02-09 |
Hoffmann-La Roche Inc. |
Pyridone compounds useful in treating Alzheimer's disease
|
|
CA2269561C
(en)
|
1998-04-22 |
2007-06-05 |
Dainippon Ink And Chemicals, Inc. |
Naphthalene derivative and liquid crystal composition comprising the same
|
|
HK1040076A1
(zh)
|
1998-09-21 |
2002-05-24 |
希雷生物化学有限公司 |
作为整联蛋白抑制剂的喹嗪酮
|
|
US6172216B1
(en)
|
1998-10-07 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of BCL-X expression
|
|
US6214986B1
(en)
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
|
EP1652839A3
(en)
|
1999-10-28 |
2006-07-05 |
Daiichi Pharmaceutical Co., Ltd. |
Drug efflux pump inhibitor
|
|
AU2001230426C1
(en)
|
2000-01-24 |
2006-06-22 |
Astrazeneca Ab |
Therapeutic morpholino-substituted compounds
|
|
WO2002038738A2
(en)
|
2000-11-09 |
2002-05-16 |
Cold Spring Harbor Laboratory |
Chimeric molecules to modulate gene expression
|
|
US6774134B2
(en)
|
2000-12-20 |
2004-08-10 |
Bristol-Myers Squibb Company |
Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
|
|
HUP0400639A3
(en)
*
|
2000-12-21 |
2010-03-29 |
Vertex Pharma |
Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
|
|
WO2002087589A1
(en)
|
2001-04-26 |
2002-11-07 |
Daiichi Pharmaceutical Co., Ltd. |
Medicine for inhibiting drug elimination pump
|
|
JP2005516005A
(ja)
|
2001-12-07 |
2005-06-02 |
バーテクス ファーマスーティカルズ インコーポレイテッド |
Ｇｓｋ−３阻害剤として有用なピリミジンベースの化合物
|
|
GB0205281D0
(en)
|
2002-03-06 |
2002-04-17 |
Novartis Ag |
Organic compounds
|
|
CA2493458A1
(en)
|
2002-07-24 |
2004-01-29 |
Ptc Therapeutics, Inc. |
Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
|
|
DE60326894D1
(de)
|
2002-09-30 |
2009-05-07 |
Neurosearch As |
1,4-Diazabicycloalkanderivate, deren Herstellung und Verwendung
|
|
MXPA05003344A
(es)
*
|
2002-09-30 |
2005-11-23 |
Neurosearch As |
Derivados novedosos de 1,4-diazabicicloalcano, su preparacion y uso.
|
|
US20070078144A1
(en)
|
2003-01-29 |
2007-04-05 |
Stockwell Brent R |
Agents for treating neurodegenerative diseases
|
|
WO2004113335A2
(en)
|
2003-06-20 |
2004-12-29 |
Chiron Corporation |
Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
|
|
GB0315494D0
(en)
|
2003-07-02 |
2003-08-06 |
Biofocus Plc |
Compounds which bind to the active site of protein kinase enzymes
|
|
BRPI0413234A
(pt)
|
2003-08-01 |
2006-10-03 |
Genelabs Tech Inc |
derivados de imidazola bicìclica contra flaviviridae
|
|
US7160888B2
(en)
|
2003-08-22 |
2007-01-09 |
Warner Lambert Company Llc |
[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
|
|
US20050074801A1
(en)
|
2003-09-09 |
2005-04-07 |
Monia Brett P. |
Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
|
|
US20050137203A1
(en)
|
2003-12-22 |
2005-06-23 |
Jianguo Ji |
3-quinuclidinyl amino-substituted biaryl derivatives
|
|
US7309699B2
(en)
|
2003-12-22 |
2007-12-18 |
Abbott Laboratories |
3-Quinuclidinyl amino-substituted biaryl derivatives
|
|
US7655657B2
(en)
*
|
2003-12-22 |
2010-02-02 |
Abbott Laboratories |
Fused bicycloheterocycle substituted quinuclidine derivatives
|
|
US20050245531A1
(en)
*
|
2003-12-22 |
2005-11-03 |
Abbott Laboratories |
Fused bicycloheterocycle substituted quinuclidine derivatives
|
|
KR20060127909A
(ko)
|
2003-12-24 |
2006-12-13 |
비오타 사이언티픽 매니지먼트 피티와이 엘티디 |
호흡기 다핵체 바이러스 감염 치료용 다환 물질
|
|
SE0400184D0
(sv)
|
2004-01-30 |
2004-01-30 |
Fyrkloevern Scandinavia Ab |
New therapeutical use
|
|
TW200536830A
(en)
|
2004-02-06 |
2005-11-16 |
Chugai Pharmaceutical Co Ltd |
1-(2H)-isoquinolone derivative
|
|
EP1732560A4
(en)
|
2004-04-08 |
2010-08-18 |
Neurogen Corp |
SUBSTITUTED CINNOLINE-4-YLAMINE
|
|
BRPI0510560A
(pt)
|
2004-05-04 |
2007-11-20 |
Warner Lambert Co |
pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
|
|
WO2006078834A1
(en)
|
2005-01-21 |
2006-07-27 |
Janssen Pharmaceutica N.V. |
Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
|
|
US7879992B2
(en)
|
2005-01-31 |
2011-02-01 |
Isis Pharmaceuticals, Inc. |
Modification of MyD88 splicing using modified oligonucleotides
|
|
JP2006219453A
(ja)
|
2005-02-14 |
2006-08-24 |
Tokyo Univ Of Pharmacy & Life Science |
キノリン環を母核とする金属識別型二波長性蛍光分子
|
|
US7563601B1
(en)
|
2005-06-01 |
2009-07-21 |
City Of Hope |
Artificial riboswitch for controlling pre-mRNA splicing
|
|
MX2007015675A
(es)
*
|
2005-07-04 |
2008-02-20 |
Novo Nordisk As |
Antagonistas del receptor de histamina h3.
|
|
US8258109B2
(en)
|
2005-10-20 |
2012-09-04 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of LMNA expression
|
|
US20070105807A1
(en)
|
2005-11-10 |
2007-05-10 |
Sazani Peter L |
Splice switch oligomers for TNF superfamily receptors and their use in treatment of disease
|
|
JP5425474B2
(ja)
|
2006-01-26 |
2014-02-26 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
ハンチンチン対する、組成物及びその使用
|
|
JP5213723B2
(ja)
|
2006-01-27 |
2013-06-19 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物
|
|
AR059339A1
(es)
|
2006-02-09 |
2008-03-26 |
Chugai Pharmaceutical Co Ltd |
Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
|
|
US8110681B2
(en)
|
2006-03-17 |
2012-02-07 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Compounds for the treatment of spinal muscular atrophy and other uses
|
|
WO2007130383A2
(en)
*
|
2006-04-28 |
2007-11-15 |
Northwestern University |
Compositions and treatments using pyridazine compounds and secretases
|
|
US20080247964A1
(en)
*
|
2006-05-08 |
2008-10-09 |
Yuelian Xu |
Substituted azaspiro derivatives
|
|
WO2007133756A2
(en)
|
2006-05-15 |
2007-11-22 |
Neurogen Corporation |
Crf1 receptor ligands comprising heteroaryl fused bicycles
|
|
WO2007135121A1
(en)
|
2006-05-23 |
2007-11-29 |
Neurosearch A/S |
Novel 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use
|
|
EP2079724B1
(en)
|
2006-07-20 |
2010-05-26 |
Amgen Inc. |
Substituted pyridone compounds and methods of use
|
|
US8337941B2
(en)
|
2006-07-27 |
2012-12-25 |
The Trustees Of Columbia University In The City Of New York |
Fluorescent substrates for monoamine transporters as optical false neurotransmitters
|
|
US20100029685A1
(en)
*
|
2006-10-25 |
2010-02-04 |
Neurosearch A/S |
Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
|
|
US8314119B2
(en)
*
|
2006-11-06 |
2012-11-20 |
Abbvie Inc. |
Azaadamantane derivatives and methods of use
|
|
DE602007012308D1
(de)
|
2006-12-22 |
2011-03-10 |
Avexa Ltd |
Bicyclische pyrimidinone und deren verwendung
|
|
US20080171792A1
(en)
|
2006-12-28 |
2008-07-17 |
Jobdevairakkam Christopher New |
Use of highly concentrated formulations of 4-phenylbutyrate for treatment of certain disorders
|
|
FR2914188B1
(fr)
|
2007-03-28 |
2012-06-22 |
Trophos |
Nouvelle composition a base d'oxime de cholest-4-en-3-one
|
|
EP2014656A3
(en)
*
|
2007-06-11 |
2011-08-24 |
High Point Pharmaceuticals, LLC |
New heteocyclic h3 antagonists
|
|
SI2193133T1
(sl)
|
2007-09-27 |
2015-12-31 |
Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii |
Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze
|
|
US20100267712A1
(en)
|
2007-09-27 |
2010-10-21 |
The United States of America, as represented by the Secretary, Department of Health and |
Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
|
|
US8153813B2
(en)
|
2007-12-20 |
2012-04-10 |
Abbott Laboratories |
Benzothiazole and benzooxazole derivatives and methods of use
|
|
US8993580B2
(en)
|
2008-03-14 |
2015-03-31 |
Intellikine Llc |
Benzothiazole kinase inhibitors and methods of use
|
|
US20090258907A1
(en)
|
2008-04-09 |
2009-10-15 |
Abbott Laboratories |
Compounds useful as inhibitors of rock kinases
|
|
WO2009131958A2
(en)
|
2008-04-21 |
2009-10-29 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising triazine derivatives
|
|
US8633019B2
(en)
|
2008-05-27 |
2014-01-21 |
Ptc Therapeutics, Inc. |
Methods for treating spinal muscular atrophy
|
|
CA2728376C
(en)
|
2008-06-20 |
2015-05-12 |
Rottapharm S.P.A. |
6-1h-imidazo-quinazoline and quinolines derivatives/mao inhibitors for treating depression
|
|
EP2138493A1
(en)
|
2008-06-26 |
2009-12-30 |
Sanofi-Aventis |
Substituted pyrimidone derivatives
|
|
US8318732B2
(en)
|
2008-07-02 |
2012-11-27 |
Avexa Limited |
Compounds having antiviral properties
|
|
WO2010019243A1
(en)
|
2008-08-13 |
2010-02-18 |
Ptc Therapeutics, Inc. |
Methods for treating viral infections
|
|
GB2465405A
(en)
|
2008-11-10 |
2010-05-19 |
Univ Basel |
Triazine, pyrimidine and pyridine analogues and their use in therapy
|
|
EP2379564A1
(en)
|
2008-12-19 |
2011-10-26 |
Schering Corporation |
Bicyclic heterocyclic derivatives and methods of use thereof
|
|
WO2010093425A1
(en)
|
2009-02-11 |
2010-08-19 |
Sepracor Inc. |
Histamine h3 inverse agonists and antagonists and methods of use thereof
|
|
FR2945289A1
(fr)
|
2009-05-11 |
2010-11-12 |
Sanofi Aventis |
Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
|
|
WO2010145208A1
(en)
*
|
2009-06-19 |
2010-12-23 |
Abbott Laboratories |
Diazahomoadamantane derivatives and methods of use thereof
|
|
NZ599032A
(en)
|
2009-09-11 |
2014-09-26 |
Isis Pharmaceuticals Inc |
Modulation of huntingtin expression
|
|
WO2011050245A1
(en)
|
2009-10-23 |
2011-04-28 |
Yangbo Feng |
Bicyclic heteroaryls as kinase inhibitors
|
|
US20150018301A1
(en)
|
2009-11-06 |
2015-01-15 |
The Johns Hopkins University |
LRRK-2-Mediated Neuronal Toxicity
|
|
US8754220B2
(en)
|
2009-11-20 |
2014-06-17 |
Merck Sharp & Dohme Corp. |
Quinolizidinone carboxamide M1 receptor positive allosteric modulators
|
|
CN102812023A
(zh)
|
2010-01-13 |
2012-12-05 |
韩国巴斯德研究所 |
抗感染吡啶并(1,2-a)嘧啶类
|
|
WO2011097644A2
(en)
|
2010-02-08 |
2011-08-11 |
Isis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
|
EP3561060A1
(en)
|
2010-02-08 |
2019-10-30 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
|
WO2011097641A1
(en)
|
2010-02-08 |
2011-08-11 |
Isis Pharmaceuticals, Inc. |
Methods and compositions useful in treatment of diseases or conditions related to repeat expansion
|
|
EP2575866A4
(en)
|
2010-05-24 |
2013-10-16 |
Presidio Pharmaceuticals Inc |
HCV NS5A INHIBITORS
|
|
US20120008349A1
(en)
*
|
2010-07-12 |
2012-01-12 |
Scharf Mesa P |
Power inverter systems with high-accuracy reference signal generation and associated methods of control
|
|
US20130225659A1
(en)
|
2010-07-19 |
2013-08-29 |
Isis Pharmaceuticals, Inc. |
Modulation of nuclear-retained rna
|
|
WO2012075393A2
(en)
*
|
2010-12-02 |
2012-06-07 |
President And Fellows Of Harvard College |
Activators of proteasomal degradation and uses thereof
|
|
WO2012104823A2
(en)
|
2011-02-04 |
2012-08-09 |
Novartis Ag |
Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
|
|
EP3467109A1
(en)
|
2011-02-08 |
2019-04-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
US8703763B2
(en)
|
2011-03-02 |
2014-04-22 |
Hoffmann-La Roche Inc. |
Bridged piperidine derivatives
|
|
US9447075B2
(en)
|
2011-08-02 |
2016-09-20 |
The Brigham And Women's Hospital, Inc. |
Pyridazine derivatives as EAAT2 activators
|
|
EP2742056B2
(en)
|
2011-08-11 |
2020-06-10 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
|
US8871756B2
(en)
|
2011-08-11 |
2014-10-28 |
Hoffmann-La Roche Inc. |
Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
|
|
EP2560008B1
(en)
|
2011-08-18 |
2016-11-30 |
Korea Institute of Science and Technology |
Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
|
|
EP2751269B1
(en)
|
2011-08-29 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
|
WO2013059606A1
(en)
|
2011-10-21 |
2013-04-25 |
Tufts Medical Center, Inc. |
Compounds and methods for the treatment of muscular disease, and related screening methods
|
|
GB201119538D0
(en)
|
2011-11-10 |
2011-12-21 |
Viral Ltd |
Pharmaceutical compounds
|
|
ES2606630T3
(es)
*
|
2011-11-28 |
2017-03-24 |
Novartis Ag |
Derivados de trifluorometil-oxadiazol novedosos y su uso en el tratamiento de enfermedad
|
|
USRE47689E1
(en)
|
2011-12-30 |
2019-11-05 |
Ptc Therapeutics, Inc. |
Compounds for treating spinal muscular atrophy
|
|
ES2733644T3
(es)
|
2012-01-26 |
2019-12-02 |
Ptc Therapeutics Inc |
Compuestos para tratar atrofia muscular espinal
|
|
JP6092897B2
(ja)
|
2012-02-10 |
2017-03-08 |
ピーティーシー セラピューティクス， インコーポレイテッド |
脊髄性筋萎縮症を治療するための化合物
|
|
EA029155B1
(ru)
|
2012-03-01 |
2018-02-28 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Соединения для лечения спинальной мышечной атрофии
|
|
CA2868026C
(en)
|
2012-03-23 |
2021-02-16 |
Ptc Therapeutics, Inc. |
Compounds for treating spinal muscular atrophy
|
|
IN2014KN02601A
(enExample)
|
2012-04-24 |
2015-05-08 |
Vertex Pharma |
|
|
US8980934B2
(en)
*
|
2012-06-22 |
2015-03-17 |
University Health Network |
Kinase inhibitors and method of treating cancer with same
|
|
WO2014012050A2
(en)
|
2012-07-13 |
2014-01-16 |
Indiana University Research & Technology Corporation |
Compounds for treatment of spinal muscular atrophy
|
|
US8729263B2
(en)
|
2012-08-13 |
2014-05-20 |
Novartis Ag |
1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
|
|
CA2887884A1
(en)
|
2012-10-12 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
|
EP4144845B1
(en)
|
2012-10-12 |
2024-04-24 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
|
US9227976B2
(en)
|
2012-10-25 |
2016-01-05 |
Usher Iii Initiative, Inc. |
Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
|
|
US9040712B2
(en)
|
2013-01-23 |
2015-05-26 |
Novartis Ag |
Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
|
|
WO2014121287A2
(en)
|
2013-02-04 |
2014-08-07 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
|
CN105026398B
(zh)
|
2013-03-05 |
2018-05-18 |
默克专利股份公司 |
用于治疗疾病诸如癌症的三唑并[4,5-d]嘧啶衍生物
|
|
WO2014184163A1
(en)
|
2013-05-14 |
2014-11-20 |
F. Hoffmann-La Roche Ag |
Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
|
|
RU2673542C2
(ru)
|
2013-06-25 |
2018-11-28 |
Ф. Хоффманн-Ля Рош Аг |
Соединения для лечения спинальной мышечной атрофии
|
|
EA030631B1
(ru)
|
2013-07-31 |
2018-09-28 |
Новартис Аг |
1,4-дизамещенные аналоги пиридазинхинолина и способы лечения состояний, связанных с smn-дефицитом
|
|
CN105392790B
(zh)
|
2013-08-19 |
2019-04-19 |
豪夫迈·罗氏有限公司 |
4H-吡啶并[1,2-a]嘧啶-4-酮化合物制备用于预防或治疗癌症的药物的用途
|
|
WO2015095449A1
(en)
|
2013-12-19 |
2015-06-25 |
Ptc Therapeutics, Inc. |
Methods for modulating the amount rna transcripts
|
|
WO2015095446A1
(en)
|
2013-12-19 |
2015-06-25 |
Ptc Therapeutics, Inc. |
Methods for modulating the amount of rna transcripts
|
|
EP3082820B1
(en)
|
2013-12-19 |
2022-07-20 |
PTC Therapeutics, Inc. |
Methods for modulating the amount of rna transcripts
|
|
ES2917473T3
(es)
|
2014-01-16 |
2022-07-08 |
Wave Life Sciences Ltd |
Diseño quiral
|
|
ES2699354T3
(es)
|
2014-01-17 |
2019-02-08 |
Novartis Ag |
Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2
|
|
AR099134A1
(es)
|
2014-01-24 |
2016-06-29 |
Hoffmann La Roche |
Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
|
|
WO2015136947A1
(en)
|
2014-03-14 |
2015-09-17 |
Raqualia Pharma Inc. |
Azaspiro derivatives as trpm8 antagonists
|
|
DK3143025T3
(da)
|
2014-05-15 |
2019-12-09 |
Hoffmann La Roche |
Forbindelser til behandling af spinal muskelatrofi
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
EP3157875A2
(en)
|
2014-06-17 |
2017-04-26 |
Novozymes A/S |
Biological phosphorus removal from wastewater
|
|
CA2952895C
(en)
|
2014-06-25 |
2023-09-26 |
F. Hoffmann-La Roche Ag |
Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy
|
|
SMT201900347T1
(it)
|
2014-12-24 |
2019-07-11 |
Uniqure Ip Bv |
Soppressione del gene huntingtina indotta da rnai
|
|
PL3244891T3
(pl)
|
2015-01-16 |
2022-12-27 |
The General Hospital Corporation |
Związki poprawiające splicing mRNA
|
|
WO2016128343A1
(en)
|
2015-02-09 |
2016-08-18 |
F. Hoffmann-La Roche Ag |
Compounds for the treatment of cancer
|
|
GB201502567D0
(en)
|
2015-02-16 |
2015-04-01 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
|
GB201506933D0
(en)
|
2015-04-23 |
2015-06-10 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
|
JP6749343B2
(ja)
|
2015-05-20 |
2020-09-02 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
脊髄性筋萎縮症を処置するための化合物
|
|
EP4249472A3
(en)
|
2015-05-30 |
2023-12-13 |
PTC Therapeutics, Inc. |
Methods for modulating rna splicing
|
|
CN108025089A
(zh)
|
2015-07-22 |
2018-05-11 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
WO2017023987A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
|
WO2017059251A1
(en)
|
2015-10-02 |
2017-04-06 |
Incyte Corporation |
Heterocyclic compounds useful as pim kinase inhibitors
|
|
JP2018533594A
(ja)
|
2015-11-12 |
2018-11-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
筋萎縮性側索硬化症を処置するための化合物
|
|
JP6659841B2
(ja)
|
2015-11-12 |
2020-03-04 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
脊髄性筋萎縮症を処置するための組成物
|
|
EP3386978B1
(en)
|
2015-12-10 |
2021-01-27 |
H. Hoffnabb-La Roche Ag |
Bridged piperidine derivatives
|
|
CN110946865B
(zh)
|
2015-12-10 |
2024-01-26 |
Ptc医疗公司 |
用于治疗亨廷顿病的方法
|
|
US10526345B2
(en)
|
2016-04-08 |
2020-01-07 |
Mankind Pharma Ltd. |
Compounds as GPR119 agonists
|
|
AR108325A1
(es)
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
|
CN109477108A
(zh)
|
2016-05-04 |
2019-03-15 |
波涛生命科学有限公司 |
寡核苷酸组合物和其方法
|
|
AU2017274199B2
(en)
|
2016-05-31 |
2021-09-23 |
Board Of Regents, The University Of Texas System |
Heterocyclic inhibitors of PTPN11
|
|
US20190264267A1
(en)
|
2016-07-25 |
2019-08-29 |
Wave Life Sciences Ltd. |
Phasing
|
|
TW202500565A
(zh)
|
2016-10-24 |
2025-01-01 |
美商傳達治療有限公司 |
Shp2磷酸酶抑制劑及其使用方法
|
|
US11857599B2
(en)
|
2017-04-03 |
2024-01-02 |
Acceleron Pharma Inc. |
Compositions and methods for treating spinal muscular atrophy
|
|
WO2018218133A1
(en)
|
2017-05-26 |
2018-11-29 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
|
|
EP3634953B1
(en)
|
2017-06-05 |
2024-01-03 |
PTC Therapeutics, Inc. |
Compounds for treating huntington's disease
|
|
MX2019015578A
(es)
|
2017-06-28 |
2020-07-28 |
Ptc Therapeutics Inc |
Metodos para tratar la enfermedad de huntington.
|
|
CN111163838B
(zh)
|
2017-06-28 |
2023-03-28 |
Ptc医疗公司 |
用于治疗亨廷顿氏病的方法
|
|
RU2020105929A
(ru)
|
2017-08-04 |
2021-09-06 |
Скайхоук Терапьютикс, Инк. |
Способы и композиции для модулирования сплайсинга
|
|
EP3755699A1
(en)
|
2018-02-21 |
2020-12-30 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of use thereof
|
|
BR112020019385A2
(pt)
|
2018-03-21 |
2021-03-30 |
Relay Therapeutics, Inc. |
Inibidores de shp2 fosfatase e métodos de uso dos mesmos
|
|
WO2019183364A1
(en)
|
2018-03-21 |
2019-09-26 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
|
|
JP7399870B2
(ja)
|
2018-03-27 |
2023-12-18 |
ピーティーシー セラピューティクス， インコーポレイテッド |
ハンチントン病を処置するための化合物
|
|
EP3814360B8
(en)
|
2018-06-27 |
2024-11-06 |
PTC Therapeutics, Inc. |
Heteroaryl compounds for treating huntington's disease
|
|
KR20210038845A
(ko)
|
2018-06-27 |
2021-04-08 |
피티씨 테라퓨틱스, 인크. |
헌팅턴병 치료를 위한 헤테로아릴 화합물
|
|
PL3814357T3
(pl)
|
2018-06-27 |
2024-09-16 |
Ptc Therapeutics, Inc. |
Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
|
|
CN114245794B
(zh)
|
2019-05-13 |
2024-09-13 |
Ptc医疗公司 |
用于治疗亨廷顿氏病的化合物
|
|
WO2021007378A1
(en)
|
2019-07-11 |
2021-01-14 |
Ptc Therapeutics, Inc. |
Compounds for use in treating huntington's disease
|
|
US20240216369A1
(en)
|
2019-11-01 |
2024-07-04 |
Novartis Ag |
The use of a splicing modulator for a treatment slowing progression of huntington's disease
|